Literature DB >> 3342463

Application of a new preclinical drug screening system for cancer of the large bowel.

W Scheithauer1, M P Moyer, G M Clark, D D Von Hoff.   

Abstract

We report a prospective evaluation of three human, continuous colorectal cancer cell lines and a new semiautomated radiometric technique (Bactec system) as a primary screening procedure for cytotoxic compounds with activity against cancer of the large bowel. COLO 320DM, Ht-29, and the metastatic OM-1 colon cancer cell line that have previously been shown to yield clinically relevant information in terms of drug sensitivity patterns in humans were all tested against 11 new compounds currently being investigated in phase I or early phase II clinical trials. Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer.

Entities:  

Mesh：

Year:  1988        PMID： 3342463     DOI： 10.1007/bf00262734

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  14 in total

Review 1.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

2.  Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents.

Authors:  A A Ovejera; D P Houchens
Journal:  Semin Oncol       Date:  1981-12       Impact factor: 4.929

3.  Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.

Authors:  L A Quinn; G E Moore; R T Morgan; L K Woods
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

4.  A new method for in vitro chemosensitivity assay: inhibition of metabolic CO2 production.

Authors:  N B Kurnick; H A Coats; I de Jesus
Journal:  Biomed Pharmacother       Date:  1983       Impact factor: 6.529

5.  The use of human cancer cell lines as a primary screening system for antineoplastic compounds.

Authors:  G J Finlay; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1984-07

6.  Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.

Authors:  D W Fry; J A Besserer; T J Boritzki
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

7.  Phase I pharmacotoxicology study of human fibroblast interferon in human cancers.

Authors:  T A McPherson; Y H Tan
Journal:  J Natl Cancer Inst       Date:  1980-07       Impact factor: 13.506

8.  Characterization of two metastatic subpopulations originating from a single human colon carcinoma.

Authors:  E N Spremulli; C Scott; D E Campbell; N P Libbey; D Shochat; D V Gold; D L Dexter
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

9.  Use of a radiometric system to screen for antineoplastic agents: correlation with a human tumor cloning system.

Authors:  D D Von Hoff; B Forseth; L E Warfel
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

10.  In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.

Authors:  W Scheithauer; D D Von Hoff; G M Clark; J L Shillis; E F Elslager
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08
View more
  5 in total

Review 1.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

2.  Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Authors:  Y Sasaki; T Shinkai; K Eguchi; T Tamura; Y Ohe; T Ohmori; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Authors:  G Schwartsmann; P Dodion; J B Vermorken; W W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; W J van der Vijgh; M B van Hennik
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development.

Authors:  Satheesh Kumar Palanisamy; N M Rajendran; Angela Marino
Journal:  Nat Prod Bioprospect       Date:  2017-01-17

5.  Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill.

Authors:  D W Wilbur; E S Camacho; D A Hilliard; P L Dill; L M Weisenthal
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.